Kornimate/medical-research-clean huggingface dataset:
preimplantation genetic screening in ivf treatment

Conditions: Infertility

Summary: this is the pilot phase of a randomised controlled trial. the purpose of the pilot study is to assess the ability to recruit, randomise, adherence to the study protocol and plan for a full study. the purpose of the full study will be to determine if a policy of embryo selection and transfer based on morphological evaluation and preimplantation genetic testing for aneuploidy (pgt-a) is a more clinically effective, safer, cost-effective and acceptable way to provide in vitro fertilisation (ivf) treatment in women of advanced reproductive age compared to the routine practice of embryo selection and transfer based on morphological evaluation alone.

the target population for the trial are women aged 35 - 42 years undergoing ivf±icsi treatment. intervention the experimental strategy will be to perform pgt-a (also referred as preimplantation genetic screening - pgs) involving trophectoderm biopsy on embryos reaching the blastocyst stage on day 5/6/7 following egg collection. all embryos will be frozen after the biopsy procedure. comprehensive chromosome screening (ccs) of all chromosomes will be performed using next generation sequencing (ngs). embryos will be categorised as euploid, mosaic euploid and aneuploid embryos and embryos will be ranked based on the degree of euploidy. only euploid embryos or mosaic euploid embryos deemed suitable to be replaced will be transferred in subsequent frozen-thawed embryo transfer cycles. comparison women in the control arm will have the fresh embryo transfer procedure on day 5 following egg collection or a frozen-thawed embryo transfer as first line if clinically indicated in keeping with current routine practice. embryo selection for transfer will be based on morphological criteria alone.

Eligibility criteria:
inclusion criteria: * inclusion criteria for the study would be women aged 35 - 42 years undergoing ivf ± icsi for treatment of infertility * patients with 3 or more good quality embryos (assessed according to the embryo scoring system of the association of clinical embryologists, uk) on day 3 following egg collection * ability to provide informed written consent exclusion criteria: * women undergoing preimplantation genetic testing for inherited genetic disorders * gamete donation cycles * untreated hydrosalpinges * untreated uterine pathology (eg: endometrial polyps, submucous fibroids, intramural fibroids \> 5 centimetres in maximum diameter, intrauterine adhesions, uterine septa)

Keywords: preimplantation genetic testing ivf rct pilot study
the effect of a non-hormonal cox-2 inhibitor (celebrex) on ovulation

Conditions: Ovulation; Luteal Development

Summary: the purpose of this study is to assess the effect that celebrex (a cox-2 inhibitor and non-steroidal anti-inflammatory drug) has on ovulation.

a prospective randomized double-blind crossover study of healthy reproductive-aged (18-35 years old) women with regular cycles, not currently using or needing hormonal contraception, were recruited. women will undergo ovarian ultrasound and serum hormone monitoring during four menstrual cycles (control cycle, treatment cycle 1, washout cycle, treatment cycle 2). subjects received study drug (oral celecoxib 400 mg or placebo) either 1) once daily starting on cycle day 8 and continuing until follicle rupture or the onset of next menses if follicle rupture did not occur (pre-lh surge dosing) or 2) once daily beginning with the lh surge and continued for 6 days (post-lh surge dosing). women will be randomly assigned to one of the above treatment schemes and received the other in the subsequent treatment cycle. this study aims to determine if treatment with a highly selective cox2 inhibitor, celecoxib, would be a more effective agent in terms of causing ovulatory dysfunction. this study also aims to determine whether treatment with celecoxib would adversely affect luteal function.

Eligibility criteria:
inclusion criteria: * age 18-35 * currently not using hormonal contraception * cycle length between 26-34 days * general good health (specifically no hx of: diabetes, cardiac problems, moderate/severe heart burn (gerd), obesity (bmi \> 30), hypertension (bp \> 130/80) * willing and able to agree to randomization and informed consent * willing and able to use a menstrual diary to chart bleeding serum progesterone \> 3 ng/ml (from cycle day 18-25) * willing and able to return to clinic for bi-weekly for blood tests and ultrasounds throughout cycles 2, 3 \& 5 exclusion criteria: * diabetes * cardiac disease * moderate to severe heart burn (or gerd) obesity (bmi \> 30) hypertension (bp \> 130/80) * allergy to nsaids * currently pregnant or trying to conceive * polycystic ovarian syndrome * use of hormonal contraception (participants can use barrier methods, spermicide, female or male sterilization, copper intrauterine device, abstinence, or have female partners

Keywords: celebrex prostoglandin inhibitor ovulation emergency contraception
effects of open and laparoscopic gastrointestinal surgery on gastrointestinal function

Conditions: Postoperative Ileus

Summary: a prospective study to compare the postoperative ileus in open and laparoscopic gastrointestinal surgery through the determination of the time the patient takes to pass flatus, pass stool, bowel movement, oral intake, the time of hospital stay and total hospital costs. postoperative ileus (poi) is one of the major focus of concern for surgeons, hospital executives, quality assurance directors as well as patients because of its role in causing patient distress, discomfort, and morbidity, leading to an increase in the duration of hospital stay and cost of care.

all patients aged ≥18 years scheduled to undergo gastric and colorectal cancer resection surgery at the department of gastrointestinal surgery, west china hospital between 2019 to 2020 will be screened for eligibility. the inclusion criteria for the study will be the patient undergoing elective gastric cancer surgery, have the american society of anesthesiologist (asa) grade ≤ iii, alert consciousness, and bmi, and accurate preoperative diagnosis of gastric adenocarcinoma on the basis of computed tomography ct scan report, gastroscopy and histopathological reports. exclusion criteria will be those who cannot participate in study assessments owing to the language barrier, dementia or postoperative delirium; previously received palliative surgery, develops early postoperative bowel obstruction, anastomotic leakage or gastroparesis, those requiring reoperation for any other indication before the commencement of formal assessment for ppoi. those requiring more than 30 minutes of adhesiolysis. each patient will be approached during preoperative counseling on an individual basis by one of the authors (yz)

Eligibility criteria:
inclusion criteria: * patients aged ≥18 years scheduled to undergo elective abdominal surgery * american society of anesthesiologist (asa) grade ≤ iii * alert consciousness * any bmi * accurate preoperative diagnosis on the basis of necessary reports exclusion criteria: * cannot participate in study assessments owing to the language barrier, dementia or postoperative delirium * previously received palliative surgery * develops early postoperative bowel obstruction, anastomotic leakage or gastroparesis * those requiring reoperation for any other indication before the commencement of formal assessment for poi * those requiring more than 30 minutes of adhesiolysis * emergency cases * american society anesthesia (asa) class iv or v patients, pregnancy, patient with abdominal carcinomatosis or radiation enteritis, inoperable cases due to metastasis, patients simultaneously enrolled in any other competing for clinical study and violation of study protocol by the patient or patient care team

Keywords: postoperative ileus prospective study case-control open surgery laparoscopic surgery bowel recovery intestinal recovery gut recovery
empathy in frames: animated cartoons to reduce hiv stigma among south african young adults

Conditions: HIV-related Stigma

Summary: this study looks at whether using cartoons that reflect the culture of south africa can help change how young adults there think about hiv/aids. this study will test two types of cartoons in a two-arm (treatment, comparator) randomized controlled trial design-one with black characters and one with white characters-to see how they affect people's attitudes and knowledge about hiv/aids. randomly allocated participants will be black seronegative south african adults between 18 and 35 years old. this group was chosen because they're a demographic disproportionately affected by hiv, they're at a high point in their lives for shaping and sharing beliefs, and they're also highly active online, which is where this study takes place. the cartoons will show the daily struggles of the protagonist living with hiv/aids, and end with a call to action. the study aims to highlight how the characters' ethnicity influences how viewers feel about and remember the message. the investigators want to understand if seeing characters who look like them helps people understand and empathize more. the aim of this study is to learn how cultural representation can improve health communication and guide future efforts to reduce stigma in different communities. ultimately, the investigators hope this study will contribute to better public health messages and create a more accepting environment for people with hiv/aids.


Eligibility criteria:
inclusion criteria: * must self-identify as black south african * must be hiv seronegative * age range: 18-35 years * must currently reside in south africa * must have basic english language comprehension * must have internet access to view video content exclusion criteria: * prior participation in hiv stigma reduction interventions * hiv seropositive status * non-black south african identity * outside target age range (18-35)
the effects of cervical mobilization on cognitive performance

Conditions: Pain, Chronic

Summary: non spesific cervical pain syndromes are the most common cervical pathologies encountered in clinical practice. non spesific cervical pain syndrome occurs as a result of postural deformities. massage and mobilization techniques are used in the treatment of non spesific cervical pain syndrome due to their analgesic effects. the cyriax mobilization technique is a manual therapy method applies to correct the limitation of movement in the joint and to relieve pain and functional disorders. many studies have shown that cyriax mobilization technique provides faster and momentary painless joint movement compared to other physical therapy modalities. cervical mobilisation techniques also have regulator effect on autonomic nerve system. cervical mobilisation also has positive effects on anxiety and tension.

in this study, 32 patients with age range 18-65 who applied to kırşehir ahi evran university training and research hospital were examined. the individuals included in the study were divided into two groups according to the paired randomization method. these groups were control and intervention groups. traditional physiotherapy methods were applied to the control group, traditional physiotherapy and cyriax mobilisation techniques were applied to the intervention group. traditional physiotherapy methods were included; transcutaneous electrical nerve stimulation (tens), ultrasound (us), isometric strengthening exercises. for the evaluation of patients; visual analogue scale (vas), cervical goniometric measurements, lowett muscle test, burdon test and beck anxiety test were used.

Eligibility criteria:
inclusion criteria: * who had cervical pain longer than six weeks * getting at least five points from neck disability index exclusion criteria: * who had neck surgery, * who had traumatic spinal cord injury, * clinical diagnosis of radiculopathy, * clinical diagnosis of myelopathy (sensory or motor deficit), * clinical diagnosis of neurological or rheumatologic disease and structural scoliosis

Keywords: pain mobilisation anxiety
evaluate rituximab in obtaining pcr (polymerase chain reaction) negative leukapheresis product in patients with relapsed follicular lymphoma

Conditions: Non-Hodgkins Lymphoma

Summary: researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.

following the first relapse, patients with follicular type of non-hodgkin's lymphoma may have an option to receive high dose chemotherapy followed by autologous (from you) blood stem cell transplantation. one of the common causes of relapse is persistence of lymphoma cells in the bone marrow and in the collected stem cell products. patients who do not have a complete response after traditional chemotherapy, have a greater chance of the lymphoma returning even after receiving high dose chemotherapy with stem cell transplantation. in order to improve the response and decrease the relapse rate, additional therapy may be used to kill the lymphoma cells by using antibodies both before and after the transplantation. antibodies are protein made by white cells in our body to fight off infection and sometimes tumor. rituxan (rituximab) is an antibody that is effective against your type of lymphoma. researchers have reported that patients show an improved response and a lower chance of relapse when using rituximab with high dose chemotherapy with autologous stem cell transplantation. it is unknown how effective rituximab is in clearing persistence of minimal remaining disease in patients with follicular lymphoma.

Eligibility criteria:
inclusion criteria: * patients with biopsy-proven refractory cd20+ (cluster of differentiation antigen 20) follicular lymphoma or transplant eligible mantle cell lymphoma in cr1 (complete remission 1) or later. * patients must be transplant eligible per kucc bmt sop (kansas university cancer center bone marrow transplant standard operation procedures) with chemo-sensitive/marrow negative disease. * patients planning to harvest and hold may also be included as long as above criteria are met. exclusion criteria: * pregnancy * zubrod performance status greater than 2 * life expectancy is severely limited by concomitant illness. * uncontrolled arrhythmias or symptomatic cardiac disease precluding transplantation * symptomatic pulmonary disease precluding transplantation * serum creatinine greater than 1.8 mg/dl * serum bilirubin greater than 2 x upper limit of normal, sgpt (serum glutamate pyruvate transaminase) greater than 3 times upper limit of normal * evidence of chronic active hepatitis or cirrhosis * unable to sign informed consent. * allergy to rituximab

Keywords: non-hodgkins lymphoma stem cell transplant
study comparing esomeprazole magnesium 40mg once daily versus lansoprazole 30 mg twice daily in symptom control of subjects with persistent gastrooesophageal reflux disease (gerd)

Conditions: Heartburn; Gastroesophageal Reflux Disease

Summary: a double-blind study comparing esomeprazole magnesium 40 mg once daily and lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (gerd) with continued heartburn symptoms with a course of therapy of 30 mg twice daily lansoprazole.


Eligibility criteria:
inclusion criteria: * subjects must have reported history of heartburn symptoms whilst on lansoprazole 30 mg twice daily during the 30 days prior to screening. * subjects must have a minimal cumulative heartburn score of at least 4 for a minimum of 14 days, where zero = none, one = mild, two = moderate, three = severe. exclusion criteria: * subjects history of esophageal ulcers, esophageal strictures, esophageal neoplasms, gastric or duodenal ulcers, or any other significant gastric or esophageal pathology judged to be clinically significant by the investigator. * subjects with persistent heartburn symptoms while on lansoprazole 30 mg twice daily for a period of \> 6 months * subjects with a history of severe hepatic insufficiency (specifically, childs-pugh class c liver disease) that may adversely affect the metabolism abd pharmacokinetics of esomeprazole and/or lansoprazole.

Keywords: nexium esomeprazole magnesium gastroesophageal reflux disease heartburn
comparison of remdesivir versus lopinavir/ ritonavir and remdesivir combination in covid-19 patients

Conditions: Covid19

Summary: comparison outcomes of a large cohort of moderate and severe covid-19 patients received remdesivir alone with patients who received remdesivir in combination with lopinavir/ ritonavir in addition to standard management.

aim of the study 1. to assess the difference in patients' clinical status improvement between patients receiving remdesivir alone and patients receiving remdesivir and lopinavir/ ritonavir. 2. to detect time to improvement in oxygenation among both groups. 3. to detect duration of hospitalization and mortality rate in both groups. 4. to detect incidence and duration of mechanical ventilation in both treatment arms. 5. to monitor of adverse events of both drugs.

Eligibility criteria:
inclusion criteria: * hospitalized adult patients with pneumonia evidenced by chest ct scan. * laboratory (rt-pcr) confirmed infection with 2019-ncov or strongly suspected to be infected with sars-cov2 with confirmation studies pending. * and at least one of the following: 1. respiratory frequency ≥30/min. 2. blood oxygen saturation ≤93% on room air (ra). 3. partial pressure of arterial oxygen to fraction of inspired oxygen ratio (pao2/fio2) \<300. 4. worsening of lung involvement, defined as an increase in number and/or extension of pulmonary areas of consolidation, need for increased fio2 to maintain stable o2 saturation, or worsening o2 saturation of \>3% with stable fio2. exclusion criteria: * baseline elevation of alanine aminotransferase (alt) or aspartate aminotransferase (ast) levels \> 5-fold the upper limit of the normal range. * pregnancy. * known hypersensitivity to drugs or any component of the formulation. * serious co-morbidity, including: hepatic patients child pugh class c.

Keywords: remdesivir lopinavir/ ritonavir
helping hospitalized patients quit smoking

Conditions: Tobacco Abuse Cigarette

Summary: the study is being done to determine whether an in-hospital intervention using a brief intervention to facilitate quitline utilization will increase quitline utilization by hospitalized smokers, and will increase post hospital discharge smoking abstinence rates. study participants will be randomized to receive either a brief quitline facilitation intervention , or a control intervention of a brief stop-smoking message. the study will also compare healthcare costs and utilization in the first six months following hospitalization between the two groups.


Eligibility criteria:
inclusion criteria: current smoker, resident of olmsted county, inpatient admission to st. marys or rochester methodist hospital, able to participate fully in all study aspects, available for follow-up exclusion criteria: current active treatment for tobacco use initiated prior to hospitalization
treatment results on patients with debridement and prosthesis retention in the hip

Conditions: Infection; Debridement With Prosthesis Retention

Summary: this study presents the investigators results on patients treated for infection in the implemented hip prosthesis. debridement and prosthesis retention is the method, followed by antibiotic treatment. the investigators present treatment results, predisposing factors and microbiological data.


Eligibility criteria:
inclusion criteria: * infection in prothesis in hip treated with debridement and prosthesis retention exclusion criteria: * other technique

Keywords: antibiotic therapy microbiological diagnosis
adrenal insufficiency in critical emergencies in digestive diseases

Conditions: Digestive Diseases; Adrenal Insufficiency; Gastrointestinal Bleeding; Variceal Bleeding; Acute Pancreatitis

Summary: observational study about the incidence of relative adrenal insufficiency in patients with cirrhosis and acute variceal bleeding; in patients with acute peptic gastrointestinal bleeding and without liver disease; and in patients with severe acute pancreatitis. this is a study using pharmaceutical specialties in the approved conditions of use.

observational, prospective, open-label, in-patient study, that includes patients with upper gastrointestinal bleeding of variceal or peptic origin, and in patients with severe acute pancreatitis. the adrenal function of every patient included will be evaluated in the first 24 hours of admission this assessment shall be performed using the corticotropin-stimulation short test (synacthen test), that includes serum and saliva determination of cortisol, in basal conditions and 30 and 60 minutes after the administration of 250 ug of corticotropin synthetic (synacthen, novartis pharma ag, basel, switzerland). the cortisol levels will be determined by competitive immunoassay using direct chemoluminescence technology (bayer corporation, pittsburgh, pa, usa). in patients with severe acute pancreatitis all of these determinations will be repeated at the third day of admission. several other clinical and biochemical features will be recorded.

Eligibility criteria:
inclusion criteria (one of the following): * presence of acute upper gastrointestinal bleeding (variceal or peptic) + presence of hypovolemic shock (defined as a systolic blood pressure \ 100 ppm), or hb \< 80 g / l; * acute pancreatitis (diagnosed by clinical, radiological and biochemical features)with severity criteria (at least one of the following: index of ranson \> 3, apache ii \> 8 or cpr\> 120 mg/l, balthazar ct grade e) exclusion criteria: * age \ 80 years. * pregnancy. * patient refusal to participate in the study. * prior corticosteroids treatment(oral or topical). * treatment during the 30 days prior to inclusion with any of the following drugs: contraception, etomidate, ketoconazole, rifampin or phenytoin. * history of cranial trauma or surgery. * any malignancy in treatment or progression. * hiv infection. * prior known adrenal pathology. * patients not eligible to any active treatment because the existence of any clinical condition considered terminal. * patients with associated traumatic blood loss, or any other extraintestinal source of active bleeding. * burns. * patients who have been previously included in this study.

Keywords: adrenal insufficiency gi bleeding portal hypertension acute pancreatitis critical emergencies in digestive diseases severe acute pancreatitis